Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hormone drug tested in first human trial

NCT ID NCT07016802

First seen Apr 15, 2026 · Last updated Jun 09, 2026 · Updated 5 times

Summary

This early-stage study tests a new injection called GenSci134 in healthy adults and in patients with adult growth hormone deficiency. The main goal is to check safety and side effects. The study is currently recruiting 64 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT GROWTH HORMONE DEFICIENCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University Third Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100083, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

pituitary dwarfism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.